Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Up 4.5% – Time to Buy?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) rose 4.5% during trading on Monday . The stock traded as high as $12.01 and last traded at $11.95. Approximately 371,678 shares changed hands during mid-day trading, a decline of 72% from the average daily volume of 1,304,689 shares. The stock had previously closed at $11.43.

Wall Street Analysts Forecast Growth

Separately, StockNews.com initiated coverage on shares of Tonix Pharmaceuticals in a report on Monday, February 10th. They set a “sell” rating for the company.

Tonix Pharmaceuticals Price Performance

The stock’s fifty day moving average is $29.00 and its 200-day moving average is $24.42. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.33 and a quick ratio of 2.81. The stock has a market cap of $22.35 million, a PE ratio of 0.00 and a beta of 2.07.

Institutional Trading of Tonix Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in TNXP. Commonwealth Equity Services LLC acquired a new stake in Tonix Pharmaceuticals in the fourth quarter valued at approximately $40,000. PFG Investments LLC purchased a new position in Tonix Pharmaceuticals in the fourth quarter valued at approximately $72,000. Northern Trust Corp purchased a new position in Tonix Pharmaceuticals in the fourth quarter valued at approximately $162,000. Jane Street Group LLC increased its stake in Tonix Pharmaceuticals by 5,932.3% in the fourth quarter. Jane Street Group LLC now owns 1,662,682 shares of the company’s stock valued at $548,000 after purchasing an additional 1,635,119 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in Tonix Pharmaceuticals by 1,600.1% in the fourth quarter. Geode Capital Management LLC now owns 1,971,894 shares of the company’s stock valued at $650,000 after purchasing an additional 1,855,907 shares during the last quarter. Institutional investors and hedge funds own 82.26% of the company’s stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.